Aurobindo Pharma USA Inc. is recalling 9,890 bottles of Rasagiline (rasagiline mesylate) 0.5mg tablets distributed under the Mylan brand. The recall was initiated because the tablets failed dissolution testing, which means the medication may not dissolve properly in the body as intended. This prescription drug, packaged in 30-count bottles, is used to treat symptoms of Parkinson's disease.
If the tablets do not dissolve correctly, the patient may not receive the intended dose of the medication, potentially leading to a lack of effectiveness in managing symptoms. No injuries or adverse events have been reported in connection with this issue.
You have 2 options:
Recall number D-1171-2023. Distributed by Mylan Pharmaceuticals Inc.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.